Alto Neuroscience, Inc. (ANRO) analyst actions
Rating and price-target actions on ANRO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ANRO overview →
7 measured ANRO analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression | Press release | -1.27% | -5.71% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Shareholders to Reach Out | Press release | +0.00% | +3.95% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out | Press release | +0.00% | -0.25% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Shareholders to Reach Out | Press release | +0.20% | +1.94% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out | Press release | -0.68% | -4.31% | |
| Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia | Press release | +0.00% | -2.21% | |
| Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder | Press release | +0.00% | +0.85% |
Keep exploring
More ANRO: earnings → · SEC filings → · ANRO overview →